NEW YORK, NY--(Marketwired - Jan 14, 2014) - While Nuvilex, Inc. (
As Nuvilex and MMS COO Dr. Gerald Crabtree has said, it is the company's intent to be a leader in the industry, and to use its expertise in the biotechnology space to drive research that lends to the marijuana debate. He said, "MMS plans to develop treatments, which employ constituents of Cannabis together with the Cell-in-a-Box™ cellulose-based live-cell encapsulation technology, for some of the deadliest forms of cancer."
Patients in search of what potential answers could come from using constituents of Cannabis together with the cell encapsulation technology, need look no further than what has been accomplished with Cell-in-a-Box™ in both pancreatic cancer clinical trials and diabetes studies. Now MMS could use that same approach to bolster research being done in glioblastoma multiforme (GBM), a type of brain cancer highly resistant to current anticancer treatments.
It is crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease, and MMS may be able to address this deadly cancer using the Cell-in-a-Box™ technology.
Nuvilex is currently into its preparations for late-phase clinical trials in advanced, inoperable pancreatic cancer using Cell-in-a-Box™, and these trials will only add to the experience the company's executives will have using this technology. Given the solid team they're putting together at MMS, they will likely use that experience to enhance the medical marijuana industry's search for cures to many types of cancer.
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com.